The Biological Testing Facility, funded under contract with the Contraception Discovery and Development Branch (CDDB) (formerly the Contraception and Reproductive Health [CRH] Branch) fulfills a unique role in bridging the discovery of contraceptive targets to the development and approval of contraceptive products in the CDDB. It carries out biological safety and efficacy evaluations of new drugs with the goal of satisfying the regulatory requirements necessary to be able to introduce the new entities into clinical trials.
The facility screens submissions of drugs for classical endocrine and anti-fertility activity and establishes potency ratios for those that exhibit significant effects. It has also developed methods for determining the duration of hormonal activity following oral, subcutaneous, or transdermal administration.
The work done by the Biological Testing Facility allows researchers to assess the potential clinical utility of new compounds and formulations.